Skip to content

In the BioHarmony Drug Report Database

Methotrexate

Methotrexate, Otrexup, Otrexup Pfs, Rasuvo, Reditrex, Jylamvo, Nordimet (methotrexate) is a small molecule pharmaceutical. Methotrexate was first approved as Methotrexate on 2013-10-11. It is used to treat breast neoplasms, choriocarcinoma, crohn disease, esophageal neoplasms, and hydatidiform mole amongst others in the USA. It has been approved in Europe to treat arthritis, juvenile arthritis, precursor cell lymphoblastic leukemia-lymphoma, psoriasis, and psoriatic arthritis amongst others. The pharmaceutical is active against dihydrofolate reductase. In addition, it is known to target reduced folate transporter, proton-coupled folate transporter, and thymidylate synthase. Methotrexate's patents are valid until 2031-05-27 (FDA).
Trade Name Jylamvo, Nordimet
Common Name Methotrexate
Indication arthritis, breast neoplasms, choriocarcinoma, crohn disease, esophageal neoplasms, hydatidiform mole, juvenile arthritis, leukemia, lung neoplasms, mycosis fungoides, osteosarcoma, precursor cell lymphoblastic leukemia-lymphoma, psoriasis, psoriatic arthritis, rheumatoid arthritis, stomach neoplasms, testicular neoplasms
Drug Class Antimetabolites (folic acid derivatives)
Methotrexate
Get full access now